|
Xerostomia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Wolf-Hirschhorn Syndrome
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
In this study, we have utilized fluorescence in situ hybridization to further characterize a WHS patient previously demonstrated to have an interstitial deletion and demonstrate that the distal breakpoint occurs between the loci FGFR3 and D4S168.
|
9215768 |
1997 |
|
Wolf-Hirschhorn Syndrome
|
0.030 |
Biomarker
|
disease |
BEFREE |
The t(4;14) translocation occurs frequently in multiple myeloma (MM) and results in the simultaneous dysregulated expression of 2 potential oncogenes, FGFR3 (fibroblast growth factor receptor 3) from der(14) and multiple myeloma SET domain protein/Wolf-Hirschhorn syndrome candidate gene 1 from der(4).
|
11157491 |
2001 |
|
Wolf-Hirschhorn Syndrome
|
0.030 |
Biomarker
|
disease |
BEFREE |
The WHS critical region (WHSCR) lies between the Huntington's disease gene, HD, and FGFR3.
|
11152656 |
2001 |
|
Wide-cupped costochondral junctions
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Wide anterior fontanel
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Waldenstrom Macroglobulinemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, we tested FGFR3 as a therapeutic target in WM and tested the effect of dovitinib on cell proliferation and apoptosis of WM cells in the context of BM microenvironment.
|
21521775 |
2011 |
|
Visual Impairment
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Visual field defects
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
|
Virus Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
In contrast, zero of six rabbits inoculated with 729.ACH.p13 cells failed to establish viral infection, whereas six of six rabbits inoculated with wild-type HTLV-1-expressing cells (729.ACH) were infected as measured by antibody responses, proviral load, and HTLV-1 p19 matrix antigen production from ex vivo-cultured PBMC.
|
16537614 |
2006 |
|
Verrucous epidermal nevus
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Analysis of mutations in the PIK3CA and FGFR3 genes in verrucous epidermal nevus.
|
24346875 |
2014 |
|
Verrucous epidermal nevus
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Fibroblast growth factor receptor 3 (FGFR3) mutation in a verrucous epidermal naevus associated with mild facial dysmorphism.
|
17441958 |
2007 |
|
Ventricular Septal Defects
|
0.010 |
GeneticVariation
|
group |
BEFREE |
There were significant differences in ACH and AEH between the groups (control vs VSD with ACP vs VSD with ACP and AR, median ACH [%], 35.1 vs 32.0 vs 22.1; median AEH [%], 52.0 vs 48.0 vs 34.4, respectively; P < 0.01]).
|
28108755 |
2017 |
|
Uterine Cervical Neoplasm
|
0.510 |
GeneticVariation
|
disease |
BEFREE |
A large proportion of these tumors (39%) harbored somatic activating FGFR3 mutations, identical to those associated with skeletal dysplasia syndromes and bladder and cervical neoplasms.
|
15772091 |
2005 |
|
Uterine Cervical Neoplasm
|
0.510 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Uterine Cervical Neoplasm
|
0.510 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Urothelial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We argue that routine use of molecular genomic tumour analysis in UC may inform selection of patients for appropriate trials and we further investigate the potential of FGFR3 as a meaningful clinical target for this difficult disease.
|
27271022 |
2016 |
|
Urothelial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.
|
19621447 |
2009 |
|
Urothelial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in FGFR3 are known to be associated with urothelial carcinoma and have a positive predictive value of 95% when detected in patients with no history of TCC.
|
22873290 |
2012 |
|
Urothelial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The frequency of FGFR3 aberrations was higher in bladder UC (25%) than in UC of the renal pelvis and ureter (18%) but the difference was not statistically significant (P = 0.444).
|
30064409 |
2018 |
|
Urothelial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this review, we discuss the biologic and prognostic impact of FGFR3 mutations in UC as well as FGFR3 as a potential target for novel therapeutics.
|
22285006 |
2013 |
|
Urothelial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Absent clinical activity suggests that patient selection by pFGFR3 IHC alone does not enrich for response to FGFR3 kinase inhibitors in urothelial carcinoma.<i></i>.
|
27932416 |
2017 |
|
Urothelial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FGFR3 immunohistochemistry staining is present in one third of primary muscle-invasive UCs and half of metastases, while FGFR3 mutations and copy number changes are relatively uncommon.
|
24846059 |
2014 |
|
Urothelial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
• Paraffin-embedded transurethral resection tissue from 113 patients with UC was investigated for the association of p85aPI3K, p-AKT, p-mTOR, p-p70S6K and p-4E-BP1 (eukaryotic initiation factor 4E-binding protein 1) expression status, as well as PIK3CA and AKT1 mutations with p-extracellular signal-regulated kinase 1/2 (ERK1/2), fibroblast growth factor receptor 3 (FGFR3), pathological features, recurrence and cancer-specific survival.
|
23107319 |
2012 |
|
Urothelial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Somatic FGFR3 mutations have been reported in various cancers such as urothelial carcinoma.
|
17568799 |
2007 |